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Background: An economic evaluation was undertaken in order to assess several therapeutic 
alternatives (rosuvastatin, atorvastatin, simvastatin, and pravastatin) for the prevention of primary 
and secondary cardiovascular events in high-risk patients in Greece.
Methods: A probabilistic Markov model with five distinct states provided estimates over 
a 20-year time span. The relative effectiveness of comparators was based on the literature. 
The HellenicSCORE risk equation was used to forecast survival. The transition probabilities 
from acute myocardial infarction or stroke to death were estimated with reference to the 
Framingham study. In addition, Framingham scores were used to calculate the probability 
of nonfatal acute myocardial infarction or nonfatal stroke. Costs were estimated from the 
perspective of sickness funds and included direct medical costs valued in the year 2012. The 
total treatment cost accounted for the cost of drugs, routine examinations, and resources 
expended in the management of acute myocardial infarction, stroke, and death. The utility 
decrements used are those for the Greek population. A supplementary budget impact analysis 
was also conducted.
Results: The mean discounted quality-adjusted life years in the case of males for the rosuvas-
tatin arm were 10.18 versus 10.04, 9.94, and 9.88 for atorvastatin, simvastatin, and pravastatin, 
respectively. The mean total cost was €15,392, €16,438, €17,009, and €17,356 for rosuvastatin, 
atorvastatin, simvastatin, and pravastatin, respectively. Similar results were obtained in the case 
of females, while all analyses demonstrated a statistically significant difference at the 95% level 
of significance. The total burden of 100% (single) use of rosuvastatin in a hypothetical cohort 
of 100 male patients for one year was €1.47 million versus €1.53 million for atorvastatin, 
€1.57 million for simvastatin, and €1.59 million for pravastatin.
Conclusion: Rosuvastatin may represent an attractive choice compared with likely alternative 
existing therapies used in the primary and secondary prevention of cardiovascular events by the 
National Health Service of Greece.
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Introduction
According to the World Health Organization, cardiovascular disease (CVD) is the 
leading cause of morbidity and mortality worldwide.1 The major risk factors associ-
ated with CVD, such as tobacco use, alcohol use, hypertension, hypercholesterolemia, 
obesity, physical inactivity, and unhealthy diet, have a high prevalence across the 
world.2 In Greece, the prevalence of cardiovascular risk factors is very high, and 
thus CVD accounts for 45.8% of all deaths in men and women.3–13 Given that the 
life expectancy of the general population in Greece is 78 years and 83 years of age 
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for males and females, respectively,3 CVD accounts for a 
considerable amount of life lost due to premature deaths in 
the country.
Apart from being a major cause of mortality and morbidity, 
CVD has an economic impact expressed in terms of direct 
health care costs, informal care costs, and loss of productiv-
ity. The total direct and indirect cost of CVD and stroke in the 
United States for 2010 was estimated at $503.2 billion.14 In 
Europe, CVD is estimated to cost €169 billion annually, with 
health care accounting for 62% of all costs.15 In this context, 
it has been noted that CVD is becoming a negative factor 
for economic growth in developing countries.16 According 
to the Agency for Healthcare Research and Quality’s guide-
lines, many forms of heart disease are largely preventable.17 
Controlling conditions such as hypertension, diabetes, and 
hypercholesterolemia can reduce the risk of heart disease. 
Statins represent the main class of drugs used in standard 
practice for reducing serum cholesterol and for preventing 
ischemic coronary disease.18 Atorvastatin, simvastatin, 
pravastatin, and rosuvastatin are among the most widely 
used statins. In particular, rosuvastatin has been shown to be 
effective in cholesterol reduction and in achieving targets for 
low-density lipoprotein cholesterol (LDL-C) levels.19–22
Health care resources are scarce in contrast with the 
increasing needs. Also, given the size of the population using 
statins, the related expenditure is significant, especially in 
light of the present fiscal status in most countries. Thus, an 
economic evaluation was undertaken in order to assess the 
cost-effectiveness of the therapeutic alternatives (rosuvastatin, 
atorvastatin, simvastatin, and pravastatin) in the prevention 
of primary and secondary cardiovascular events in Greece, 
which is going through a major financial crisis, making this 
approach to medical decision-making more important than 
ever before. The present paper presents the results of this 
economic analysis.
Materials and methods
Study objective
The aim of the present study was to conduct an economic 
evaluation comparing rosuvastatin atorvastatin, simvastatin, 
and pravastatin in the primary and secondary prevention of 
CVD among high-risk patients in Greece. Dosing in each 
case is different, and to be able to make reliable compari-
sons, we used effectiveness data corresponding to the 40 mg 
dose in each case, which has been shown to achieve at least 
a 30% reduction in LDL-C levels.27 The model assumes at 
baseline a mean age of 70 years, systolic blood pressure 
140 mmHg, total cholesterol 260 mg/dL, high-density 
lipoprotein cholesterol (HDL-C) 60 mg/dL, and computes 
results for nonsmoking males and females.
Perspective of analysis
The perspective of the economic evaluation was that of sick-
ness funds (payers) in Greece. Therefore, only direct health 
care costs reimbursed by payers were considered. Direct costs 
are those associated directly with the medical care of patients. 
Other costs that quantify the remaining nonmedical impact 
of disease (eg, productivity loss, travelling costs) were not 
considered in the present analysis.
Economic model
A Markov model was developed based on international 
experience in this field to assess the clinical and economic 
implications of using different alternatives for the primary 
and secondary prevention of events among high-risk patients 
in Greece (Figure 1).18 In the model, a population in each 
arm is simulated during a long period of time. The model 
comprises different health states in which patients can move 
over time, and each are associated with different costs and 
quality of life.
The likelihood of moving between different states is 
influenced by the effectiveness of each therapy, and hence 
the cost and quality-adjusted years of life. As illustrated in 
Figure 1, patients can transition in year-long model cycles 
from the initial state of no cardiovascu  lar event to five dis-
tinct states, including nonfatal acute myocardial infarction, 
nonfatal stroke, fatal acute myocardial infarction, fatal stroke, 
and other-cause death, representing a state in which patients 
die of causes other than a cardiovascular event. Moreover, 
patients may die in a subsequent cycle after a nonfatal acute 
myocardial infarction or stroke due to the fact that their 
mortality rates are higher.
The SCORE risk equation was calibrated recently in order 
to calculate the combined 10-year risk reflecting the prob-
ability of a patient dying due to acute myocardial infarction 
or stroke.23 To reflect the local situation, the HellenicSCORE 
calibration was used in the present analysis.24 The yearly-
converted probabilities were adjusted to include the risk 
of all-cause mortality for Greek patients according to data 
from the National Statistical Service of Greece.3 Transition 
probabilities from acute myocardial infarction or stroke to 
death were estimated based on the Framingham study.25 
In addition, Framingham scores were used to calculate 
the probability that a patient experiences a nonfatal acute 
myocardial infarction or nonfatal stroke. Thus, all event 
rates are dependent on patient age, gender, and risk status. 
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The model estimates treatment cost and quality-adjusted 
life years for alternative treatment options in an identical 
cohort of 1000 patients in each arm. Annual discount rates 
of 3.5% were applied for all outcomes, which is common 
practice in similar studies.26
Efficacy data
Treatment effectiveness was evaluated in the present 
model on the basis of LDL-C reduction with each of the 
aforementioned comparators. Data from a meta-analysis 
were used to as  sess the LDL-C reduction achieved with 
different statins.27 Estimates based on 164 placebo-
controlled trials indicate that the mean absolute reduc-
tion in LDL-C was superior in the case of rosuvastatin 
(53% for 40 mg, Table 1). It should be noted that although 
LDL-C remains the primary target of therapy, the risk 
factors included in the Framingham algorithm are based 
on total cholesterol rather than LDL-C. However, reduc-
tions in total and LDL cholesterol concentrations were 
highly correlated across trials (r = 0.83), and a bivariate 
normal distribution was assumed (based on the central 
limit theorem) in order to convert the mean reduction of 
LDL-C to a reduction in total cholesterol in a probabilis-
tic manner.27 Moreover, for practical simplicity, HDL-C 
was considered to be the same before and after treatment, 
despite the fact that rosuvastatin has been shown to be more 
efficient in the management of HDL-C levels.28
Utilities
Due to lack of appropriate data for the Greek population, 
utility weights for the nonevent state were set at 1 for all 
patients. Data regarding utility weights came from a local 
study which used the EQ-5D and have been presented 
elsewhere.12 When patients experienced a nonfatal event, 
such as stroke or acute myocardial infarction, utility dec-
rements for the whole duration of one year (equal to the 
length of the Markov cycle) were applied. For the second 
and subsequent years, different utility weights were used 
(Table 2).
Costing methodology
Costs were estimated from the perspective of sickness funds, 
and included direct medical costs valued in the year 2012. The 
AMI
Post-AMI deaths
All causes death
Stroke death No CVE
Stroke
Fatal AMI
Fatal stroke
Figure 1 Structure of the model.
Abbreviations: AMi, acute myocardial infarction; CVE, cardiovascular event.
Table 1 Absolute reduction (mmol/L) and percentage reduction 
in serum LDL-C concentration according to statin treatment*
Description** LDL-C reduction Absolute LDL-C reduction
Rosuvastatin 53% 2.56 (2.42 to 2.70)
Simvastatin 37% 1.78 (1.66 to 1.90)
Atorvastatin 49% 2.36 (2.12 to 2.59)
Pravastatin 29% 1.38 (1.31 to 1.46)
Notes: *Summary estimates from 164 randomized, placebo-controlled trials; percentage 
reductions are independent of pretreatment LDL cholesterol concentration.27 **An 
average 40 mg daily dose was assumed. Reproduced from: Quantifying effect of statins 
on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic 
review  and  meta-analysis.  Law  MR,  Wald  NJ,  Rudnicka  AR.  326:1423;2003  with 
permission from BMJ Publishing Group Ltd.27
Abbreviation: LDL-C, low-density lipoprotein cholesterol.
Table 2 Utility weights used in the model12
No event 1.00
AMi year 1 0.84
AMi year 2+ 0.93
Stroke year 1 0.70
Stroke year 2+ 0.85
Abbreviation: AMi, acute myocardial infarction.
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total cost related to each treatment includes the cost of drugs, 
the cost of acute myocardial infarction and stroke, routine 
examinations and visits to practitioners, as well as the cost of 
the resources consumed for those dying (Table 3). The total 
cost of comparators was calculated by multiplying the number 
of units of drugs required for 40 mg therapy by the unit price. 
The cost per pill for comparators was calculated using prices 
from the price bulletin of January 2012.29 In the case of ator-
vastatin, the price of its generic was used because this is the 
prevalent medication. By definition, there was no variation in 
unit costs, given that unit prices were obtained from the official 
government gazette and are common to all public hospitals in 
Greece. The cost of each comparator medication was calculated 
based on the assumption that patients take one tablet/capsule 
per day every day throughout the year until they die. Data on 
resource use for stroke and acute myocardial infarction and 
reimbursement rates were collected from recently published 
tariffs. Examinations and procedures performed on an outpa-
tient basis were valued separately. The cost of any outpatient 
regime was calculated according to the resource utilization 
proposed by experts. The cost of death was derived from the 
Greek bibliography, and a 3.5% rate was used in order to 
express the findings of this study in present values.
Analyses
The model was set to provide deterministic and probabilis-
tic analyses. The results are used to compute incremental 
cost-effectiveness ratios and cost-effectiveness acceptability 
curves. In this light, probability distributions were specified 
around all of its parameters (Table 4) and these were used 
to run simulations in order to derive expected values and 
intervals. This is important also because cost data are trun-
cated and do not follow normal distributions.30 Given that data 
are generally not normally distributed, but skewed to the right, 
bias-corrected uncertainty intervals (UI) were calculated using 
the percentile method of nonparametric simulation (using 
5000 replications). It is important to indicate that given the 
probabilistic nature of the components (as random variables), 
cost and survival of comparators could be slightly different 
and not “fixed” results produced in each experiment.
Budget impact analysis
Apart from the cost-effectiveness analysis which compares 
alternative therapeutic agents in regards to their costs and 
outcomes, a supplementary budget impact analysis was 
undertaken to forecast the future economic impact of substitu-
tion of rosuvastatin for other comparators. A straightforward 
way is to assess the economic impact of statin use within 
a lifetime horizon. Hence the results presented refer to a 
hypothetical cohort of 100 patients treated exclusively with 
each therapy in order to make easy extrapolations.
Results
The results indicate that, in the case of males, rosuvastatin 
was associated with fewer major cardiovascular events 
(stroke or acute myocardial infarction) per patient. During 
the duration of analysis, the mean number of events in the 
Table 3 Cost inputs used in the model
Costs of events Cost mean (SD)
AMi year 1 €6418 (354)
AMi year 2+ €3000 (147)
Stroke year 1 €5780 (280)
Stroke year 2+ €3000 (184)
Death €1402 (140)
Cost of medication Cost per pill
Rosuvastatin €1.735
Atorvastatin* €1.659
Simvastatin €1.106
Pravastatin €1.706
Examinations and routine tests Cost per unit (€)/ 
number
Cost per physician visit €5
Number of visits per year 5
Cost per laboratory examination €72.1
Number of laboratory examinations per year 2
Note: *Atorvastatin, generic drug.
Abbreviations: AMi, acute myocardial infarction; SD, standard deviation.
Table 4   Distributions  used  in  the  model  for  probabilistic 
analysis
Transition probabilities Distribution
Stroke to death Beta distribution
AMi to death Beta distribution
Nonfatal AMi Normal distribution
Nonfatal stroke Normal distribution
AMi and stroke mortality Normal distribution
Efficacy data
% of reduction LDL-C Normal distribution
Correlation coefficient of LDL-C and TC Normal distribution
Risk reduction for AMi and stroke Normal distribution
Utilities
AMi 1st year Beta distribution
AMi 2nd year+ Beta distribution
Stroke 1st year Beta distribution
Stroke 2nd year+ Beta distribution
Cost inputs
Drugs –
Cost of events Log-normal distribution
Cost of examinations* –
Cost of death Log-normal distribution
Note: *Common for all hospitals across the country.
Abbreviations: AMi, acute myocardial infarction; LDL-C, low-density lipoprotein 
cholesterol; TC, total cholesterol.
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rosuvastatin arm was 0.92 per patient relative to 1.46, 1.76, 
and 1.93 for atorvastatin, simvastatin, and pravastatin, 
respectively. Similarly, for women, the mean number of 
major events was 0.61 per patient against 0.92, 1.1, and 1.2 
for atorvastatin, simvastatin, and pravastatin, respectively. 
There were no differences amongst comparators for fatal 
events in either men or women. The main results are shown 
in detail in Table 5.
The mean estimate for discounted quality-adjusted 
life years in the rosuvastatin arm was 10.18 (95% UI, 
10.11–10.23) versus 10.04 (95% UI, 9.96–10.10), 9.94 
(95% UI, 9.84–10.02), and 9.88 (95% UI, 9.77–9.96) for 
atorvastatin, simvastatin, and pravastatin, respectively. 
The difference in quality-adjusted life years relative to 
rosuvastatin was 0.14 (95% UI, 0.11–0.17, P , 0.001) 
for atorvastatin, 0.24 (95% UI, 0.20–0.28, P , 0.001) for 
simvastatin, and 0.30 (95% UI, 0.25–0.35, P , 0.001) for 
pravastatin.
The mean total cost of rosuvastatin was €11,356 (95% UI, 
11,078–11,656); the cost of atorvastatin was €12,453 (95% 
UI, 12,140–12,787); the cost of simvastatin was €13,059 
(95% UI, 12,718–13,423); and the cost of pravastatin was 
€13,428 (95% UI, 13,068–13,814). Thus, rosuvastatin was 
cost-saving relative to other therapies, with a mean differ-
ence of -€1096 (95% UI, -1211, -984, P , 0.001) relative 
to atorvastatin -€1703 (95% UI, -1811, -1591, P , 0.001) 
versus simvastatin, and -€2072 (95% UI, -2181, -1964, 
P , 0.001) versus pravastatin. These data show that 
rosuvastatin represents a dominant choice against the other 
comparators in the case of male patients.
Moreover, in the case of rosuvastatin, the cost of drugs 
accounted for 53.8% of the total cost, followed by the cost of 
examinations (14.3%), cost of death (13.3%), cost of stroke 
(11.1%), and cost of acute myocardial infarction (7.5%). In 
the atorvastatin arm, the cost of drugs accounted for 46.6% 
of the total cost, followed by the cost of acute myocardial 
infarction at 17.1%, the cost of death at 13.7%, and the cost 
of examinations and stroke at 12.5% and 10.2%, respectively. 
In the case of simvastatin, the cost of drugs accounted for 
45.1% of the total cost, the cost of acute myocardial infarction 
was 21.6%, followed by the rest of the cost components with 
smaller percentages. Relatively similar results were obtained 
in the case of pravastatin.
From the point of view of budget impact, the total bur-
den of 100% (single) use of rosuvastatin in a hypothetical 
cohort of 100 patients for one year was €1.14 million versus 
€1.25 million for atorvastatin, €1.30 million for simvasta-
tin, and €1.34 million for pravastatin. Thus, the net saving 
from the use of rosuvastatin was €109,641 versus atorvas-
tatin, €170,310 versus simvastatin, and €207,190 versus 
pravastatin.
In the case of females, the mean discounted quality-
adjusted life years in the rosuvastatin arm were 10.33 (95% 
UI, 10.28–10.37) versus 10.26 (95% UI, 10.20–10.30) 10.20 
(95% UI, 10.12–10.25), and 10.16 (95% UI, 10.08–10.22) 
for atorvastatin, simvastatin, and pravastatin, respectively. 
Table 5 Markov model results in the baseline population
Cost (€) Rosuvastatin Atorvastatin Simvastatin Pravastatin
Mean 95% LUI 95% UUI Mean 95% LUI 95% UUI Mean 95% LUI 95% UUI Mean 95% LUI 95% UUI
Men 
Drugs
 
6105
 
6057
 
6145
 
5799
 
5745
 
5844
 
5621
 
5560
 
5672
 
5512
 
5444
 
5567
Cost of examinations 1629 1616 1640 1548 1533 1560 1500 1484 1514 1471 1453 1486
Cost of AMi 853 778 929 2129 2055 2207 2694 2625 2761 3057 2992 3121
Cost of stroke 1261 1247 1274 1266 1248 1285 1388 1369 1405 1438 1420 1456
Cost of death 1509 1380 1669 1711 1559 1890 1857 1680 2072 1949 1759 2185
Total cost 11,356 11,078 11,656 12,453 12,140 12,787 13,059 12,718 13,423 13,428 13,068 13,814
Effectiveness
QALYs 10.18 10.11 10.23 10.04 9.96 10.1 9.94 9.84 10.02 9.88 9.77 9.96
Cost per QALY 1116 1100 1135 1241 1222 1263 1314 1292 1340 1360 1336 1388
Women
Drugs 6321 6285 6346 6153 6114 6182 6047 5998 6081 5984 5930 6021
Cost of examinations 1687 1677 1694 1642 1632 1650 1614 1601 1623 1597 1582 1607
Cost of AMi 454 414 496 1149 1106 1190 1465 1428 1504 1673 1636 1709
Cost of stroke 946 935 956 966 950 980 1068 1054 1082 1105 1092 1119
Cost of death 1270 1171 1393 1378 1268 1515 1461 1336 1622 1514 1379 1692
Total cost 10,678 10,482 10,885 11,288 11,071 11,517 11,656 11,415 11,911 11,873 11,618 12,148
Effectiveness
QALYs discounted 10.33 10.28 10.37 10.26 10.19 10.3 10.2 10.12 10.25 10.16 10.08 10.22
Cost per QALY 1034 1022 1047 1101 1088 1116 1143 1129 1161 1168 1153 1188
Abbreviations: AMi, acute myocardial infarction; LUi, lower uncertainty interval; QALY, quality-adjusted life year; UUi, upper uncertainty interval.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
139
Economic evaluation of statins in GreeceClinicoEconomics and Outcomes Research 2012:4
The difference in quality-adjusted life years for rosuvastatin 
was 0.08 (95% UI, 0.06–0.09, P , 0.001) versus atorvas-
tatin, 0.13 (95% UI, 0.11–0.16, P , 0.001) versus sim-
vastatin, and 0.17 (95% UI, 0.14–0.20, P , 0.001) versus 
pravastatin.
The mean total cost in the case of rosuvastatin was 
€10,678 (95% UI, 10,482–10,885); the cost of atorvastatin 
was €11,288 (95% UI, 11,071–11,517); the cost of simvas-
tatin was €11,656 (95% UI, 11,415–11,911); and the cost 
of pravastatin was €11,873 (95% UI, 11,618–12,148). The 
mean difference in the cost of rosuvastatin was -€610 (95% 
UI, -1175, -918, P , 0.001) versus atorvastatin -€978 
(95% UI, -1044, -913, P , 0.001) versus simvastatin, 
and -€1195 (95% UI, -1262, -1130, P , 0.001) versus 
pravastatin. These data indicate that rosuvastatin represents 
a dominant choice against the other comparators in the case 
of female patients.
In the case of rosuvastatin, the cost of drugs accounted for 
59.2% of the total cost, followed by the cost of examinations 
at 15.8% and the cost of death at 11.9%. In the atorvastatin 
arm, the cost of drugs accounted for 54.5% of total cost fol-
lowed by the cost of examinations (14.5%), the cost of death 
(12.2%), the cost of acute myocardial infarction (10.2%), 
and finally the cost of stroke at 8.6%. Similar results were 
obtained in the case of simvastatin and pravastatin where the 
cost of drugs accounted for approximately 50% of the total 
cost of treatment.
The total burden of 100% (single) use of rosuvastatin in a 
hypothetical cohort of 100 patients was €1.07 million versus 
€1.13 million for atorvastatin, €1.17 million for simvasta-
tin, and €1.19 million for pravastatin. Thus, the net saving 
with rosuvastatin was €61,011 versus atorvastatin, €97,802 
versus simvastatin, and €119,511 versus pravastatin. These 
are significant when the total numbers of patients are taken 
into consideration. Finally, Figure 2 presents a probabilistic 
analysis against generic atorvastatin which is the least costly 
option, and it is clear that rosuvastatin maintains its domi-
nance in most cases.
Discussion
Understanding the relative benefits and costs of alternative 
treatment strategies for the primary and secondary prevention 
of cardiovascular events in high-risk patients is important in 
order to ensure that patients receive an acceptable level of 
care while effectively managing health care resources. Since 
the benefits of statins have been widely acknowledged by 
general practitioners, their use has become a part of standard 
clinical practice.
Nonetheless, it is paramount to consider the cost relative 
to the clinical benefits associated with alternative therapy 
options for high-risk patients in Greece. In the present study, 
a comparison of rosuvastatin and its main comparators 
(atorvastatin, simvastatin, pravastatin) was undertaken using 
a Markov probabilistic model. The statins selected cover 
almost the entire market in Greece, and the comparison took 
place assuming an average dose of 40 mg per day for each 
comparator for reliability purposes.
The analysis here showed that rosuvastatin is an attractive 
choice against the other aforementioned statins because it is 
associated with lower cost and slightly greater effectiveness. 
Furthermore, rosuvastatin represents a potentially cost-
saving option from a budget impact point of view in the 
Greek National Health Service setting. Probabilistic analysis 
showed that the results hold true in favor of rosuvastatin for 
both genders at a 95% level of significance. A scatter plot 
(Figure 2) in the case of rosuvastatin against atorvastatin, as 
the most prominent comparator, shows that the entire sample 
of 5000 replications falls into the southwest quadrant, which 
indicates that rosuvastatin is a slightly less costly and more 
effective choice. Similar results were obtained in the case 
of other comparisons.
The results of the current study are in agreement with 
those reported in the literature.18,31–36 In all the referenced 
cases, rosuvastatin was a dominant or cost-effective choice 
under different assumptions regarding doses, the perspec-
tive of analysis, and the characteristics of the population 
involved. From a clinical perspective, that is due to the fact 
that rosuvastatin represents an advanced therapy from a phar-
macological and clinical point of view relative to the other 
agents in this class, possesses a greater number of binding 
interactions with 3-hydroxy-3-methylglutaryl coenzyme A 
reductase, and has the longest terminal half-life among the 
statins.37 From an economic perspective, because rosuvastatin 
has a higher capacity to reduce LDL-C in relation to other 
statins, it minimizes the frequency of costly events, such as 
stroke and acute myocardial infarction.
Any model is, by necessity, a simplification of the 
process it tries to simulate, so it was necessary to make 
assumptions when constructing the model. Cardiovascular 
disease is quite a complex situation and the probability of 
experiencing or avoiding an event is subject to variability. 
CVD risk is affected by several risk factors, including 
comorbidities, demographic characteristics, dietary habits, 
treatment switches amongst statins, and dose titrations. In 
this light, the analysis was limited to high-risk patients who 
were nonsmokers with a mean age of 70 years. In addition, 
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quality of life with regard to patient age (in the case of no 
event) was ignored in the present analysis. Utility decrements 
for the rest of the states were set equal for all comparators to 
avoid possible bias. The event rates used take into consid-
eration the risk profile of patients and the model was based 
on widely accepted data.
The model assumed that a patient would be treated for 
the whole duration of interest from the start to the end of the 
model or death. Hence, no switching between treatments was 
allowed. The reason for this was the lack of appropriate data 
to populate this type of complex management. Furthermore, 
the analysis used suffers from drawbacks and limitations that 
are common in studies using similar methodologies. It does 
not represent experimental research, but instead is based on 
a model populated with data reported in the literature and on 
various assumptions, so may suffer from biases. Standard 
recommendations were followed to limit possible sources 
of bias. Thus, a systematic review and assessment of the 
evidence was performed and stochastic analysis was used 
to draw robust conclusions. This methodology and the mod-
eling approach represent a reasonable substitute for direct 
real-life comparisons between these treatments. The model 
allows a relative risk to be applied to each year of risk of 
cardiovascular events for men and women separately. The 
assumptions in the model were extracted from the literature 
and were designed to be easily tested.
The results have to be considered strictly in the Greek 
setting and on the basis of resources and drug prices. If any of 
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Figure 2 Scatter plots of rosuvastatin against atorvastatin for both genders.
Abbreviation: QALY, quality-adjusted life year.
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the underlying parameters change, so may the results and the 
conclusions of the analysis. Finally, we confined the analysis 
to sickness funds and not society overall. A broader analysis 
could be the goal of research in the future.
Conclusion
Rosuvastatin may represent an attractive option compared 
with the most likely alternative existing therapies used in the 
primary and secondary prevention of cardiovascular events 
in the National Health Service of Greece.
Disclosure
This study was funded by Astra Zeneca, Greece.
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